person
as of 2026-07-01Robert C Smith, M.D., Ph.D
Robert B Innis, M.D.Robert Bodén, Ph.D, MDRobert Buchanan, M.D.Robert C Smith, M.D.Robert Dudley, Ph.DRobert Rosenheck, M.D.Robert W Buchanan, M.D.Robert, Litman, M.D
at a glance
Roles: Principal Investigator
KOL signal score 5
0 publications · 0 high-value
Synthesized from structured facts only — each point cited above.
Profile
Affiliation
Nathan Kline Institute for Pstychiatric Research
Roles
Principal Investigator
KOL signal
5
Publications
0 (0 high-value)
Trial investigator
yes
Trials led
13
Study to Assess the Efficacy, Safety, and Tolerability of AZD8529 in Adult Schizophrenia Patients
NCT00921804Phase 2Completed
Cognitive Therapy for Distressing Visual Hallucinations: A Pilot Study
NCT02782507—Completed
Magnetic Stimulation of the Brain in Schizophrenia or Depression
NCT02905604—Completed
The Effects of Kynurenine Aminotransferase Inhibition in People With Schizophrenia
NCT04013555Phase 1, Phase 2Completed
Sodium Butyrate For Improving Cognitive Function In Schizophrenia
NCT02654405Phase 2, Phase 3Withdrawn
Rasagiline in the Treatment of Persistent Negative Symptoms of Schizophrenia
NCT00492336Phase 4Completed
Prebiotic Treatment in People With Schizophrenia
NCT05527210—Recruiting
Efficacy and Tolerability Study of Betahistine to Ameliorate Antipsychotic Associated Weight Gain
NCT00709202Phase 2Completed
Tryptophan MRI in People With Schizophrenia and Healthy Controls
NCT02067975Phase 2, Phase 3Completed
Treatment Study for Cognitive Deficits in Schizophrenia
NCT00505076Phase 2Completed
Decision Aid to Facilitate Shared Decision Making During Treatment in Schizophrenia
NCT01420575—Terminated
Imaging Cannabinoid CB1 Receptors in Schizophrenia
NCT01063335—Terminated
Efficacy Study of Galantamine for Cognitive Impairments in Schizophrenia
NCT00176423Phase 4Completed
Facts & assertions
0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
PRINCIPAL_INVESTIGATOR
trial